Zura Bio (NASDAQ:ZURA - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.
Other analysts also recently issued reports about the stock. Wedbush upped their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Oppenheimer dropped their target price on shares of Zura Bio to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, November 10th. Guggenheim reiterated a "buy" rating on shares of Zura Bio in a report on Friday, October 30th. Finally, Weiss Ratings raised shares of Zura Bio from a "sell (d-)" rating to a "sell (d)" rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zura Bio has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.
Read Our Latest Stock Analysis on Zura Bio
Zura Bio Stock Performance
ZURA opened at $0.93 on Friday. The firm has a market cap of $89.63 million, a P/E ratio of -0.83 and a beta of 0.03. The business has a 50 day moving average price of $3.54 and a 200 day moving average price of $4.96. Zura Bio has a twelve month low of $0.92 and a twelve month high of $7.44.
Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). As a group, analysts anticipate that Zura Bio will post -0.82 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Montanova Capital LLC increased its position in Zura Bio by 4.1% during the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock worth $55,714,000 after acquiring an additional 376,000 shares during the period. Commodore Capital LP acquired a new position in Zura Bio during the 1st quarter valued at $19,338,000. Affinity Asset Advisors LLC boosted its holdings in Zura Bio by 41.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company's stock valued at $15,258,000 after purchasing an additional 750,632 shares during the period. EcoR1 Capital LLC bought a new stake in Zura Bio in the 1st quarter valued at $7,019,000. Finally, Stempoint Capital LP bought a new stake in Zura Bio in the 1st quarter valued at $4,483,000. 61.14% of the stock is owned by institutional investors.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions. The company's investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.